CNS Healthcare | Clinical Neuroscience Solutions - Orlando
Status and phase
Conditions
Treatments
About
This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts.
Eligible participants will enter a 3-week Treatment Period where they will receive methylone (or placebo in Part B) once weekly for 3 weeks (3 treatment sessions). Following the Treatment Period, participants will enter a 6-week Follow-up Period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
79 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Study Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal